Literature DB >> 11380451

Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.

J Barbot1, E Costa, M Guerra, M S Barreirinho, P Isvarlal, R Robles, H E Gerritsen, B Lämmle, M Furlan.   

Abstract

We report the results of 10 years of prophylactic fresh-frozen plasma (FFP) infusion therapy in a 14-year-old girl with chronic relapsing thrombotic thrombocytopenic purpura (TTP), in whom a severe congenital von Willebrand factor (VWF)-cleaving protease deficiency has been documented. Severe haemolytic crises triggered by infections were prevented and her present renal and neurological functions have been preserved. Sequential measurements of protease activity and platelet count after FFP infusion led us to conclude tentatively that 5% may be sufficient to degrade very large and adhesive VWF multimers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380451     DOI: 10.1046/j.1365-2141.2001.02808.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

Review 3.  Thrombotic thrombocytopenic purpura: survival by "giving a dam".

Authors:  Joel L Moake
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

4.  Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome.

Authors:  Yoko Yoshida; Masanori Matsumoto; Hideo Yagi; Ayami Isonishi; Kazuya Sakai; Masaki Hayakawa; Yuji Hori; Toshiyuki Sado; Hiroshi Kobayashi; Yoshihiro Fujimura
Journal:  Blood Adv       Date:  2017-08-23

5.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

Review 6.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

7.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

Review 8.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

9.  Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child.

Authors:  A Borgi; M Khemiri; A Veyradier; K Kazdaghli; S Barsaoui
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-06-03       Impact factor: 2.576

10.  Hereditary thrombotic thrombocytopenic purpura: a case report.

Authors:  Tarcísio S Borborema; Sabrina Stephanie L Diniz; Joziele de S Lima; Fernanda F Costa; Mitiko Murao; Marcia K Campos
Journal:  Hematol Transfus Cell Ther       Date:  2020-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.